Traders should monitor upcoming investor meetings at the Piper Sandler Spring Biopharma Symposium for further commercial or partnership guidance, especially regarding Japan registration and licensing prospects. The combination of strong revenue growth, improved balance sheet, and expanding clinical validation makes FENC a potential takeover or partnership target.
Price Chart
Executive Summary
Fennec Pharmaceuticals reported strong financial and operational performance for FY 2025, with record net product sales of $44.6 million, representing 50% year-over-year growth, driven by increased adoption of PEDMARK®. The company also completed a $42 million equity offering, eliminated all debt, and advanced clinical validation of PEDMARK® through positive trial results in Japan and new real-world data in adult head and neck cancer patients.
Key Financial Metrics
Key Facts
- Full-year 2025 net product sales reached $44.6 million, up 50% YoY from $29.6 million in 2024
- Q4 2025 net product sales were $13.8 million, up 75% YoY from $7.9 million in Q4 2024
- Company raised $42 million in an oversubscribed equity offering
- Completed full debt redemption, ending 2025 with $0 debt and $36.8 million in cash
- Positive topline results from Japan's STS-J01 trial support potential PEDMARK® registration and expansion
Financial Impact
Revenue grew by $15 million YoY to $44.6 million; cash position increased by $10.2 million despite $21.5 million debt paydown
Risk Factors
- Net loss widened to $10.1 million in 2025 despite revenue growth due to higher G&A and selling expenses
- Equity offering may lead to shareholder dilution, with shares outstanding increasing from 27.5M to 34.2M
- Future growth depends on continued adoption of PEDMARK® beyond pediatric oncology into AYA and adult populations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261052 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.39 (+1.17%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.39 (−13.63%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.39 (−13.63%) |
Aug 11, 2026 11w ago | Press Release | $12.78 | awaiting T+60 | — | $10.39 (−18.70%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.39 (+13.06%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.39 (+5.06%) |
May 18, 2026 23w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.39 (+6.45%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.39 (+12.45%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.39 (+50.58%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.39 (+65.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers